Edinburgh, UK, 16th May 2019 / Synpromics Ltd, the leader in gene control, and Lonza Pharma & Biotech announce a partnership for the commercialisation of a number of inducible promoters to improve the manufacturing of biopharmaceuticals.
16
May
10
May
On the first day, CSO Michael Roberts presented to a packed room as part of the Tools & Technologies Forum. It was standing room only during his presentation: Mastering Gene Control to Enable the Next Generation of Gene Medicines.
22
Mar
David Venables presented to a full room of investors at the ARM Cell & Gene Therapy Investor Day in New York. Watch David's presentation below or view the pdf here.
05
Dec
Edinburgh, UK, 5th December 2018 / Synpromics is pleased to hear that its partner, uniQure (NASDAQ:QURE), has announced the incorporation of its promoter, developed by Synpromics, in a new preclinical research target. This follows recent positive data, presented at the ESGCT world congress, demonstrating that this highly selective liver promoter is at least eight times more potent than the current industry standard.
16
Nov
Edinburgh, UK, 16th November 2018 / Synpromics, the leader in gene control, is delighted to announce that it has been ranked 12th in the Deloitte ‘UK Technology Fast 50’ at the annual awards ceremony in London last night.